Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Other adverse events: any serious adverse event ‐ short and long term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes other adverse events: any serious adverse event ‐ short and long term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).
1 finding from 1 review
Serious adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
It is very uncertain whether long‐term red cell transfusion changes serious adverse events as a result of sickle cell‐related… compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke
It is very uncertain whether long‐term red cell transfusion changes serious adverse events as a result of sickle cell‐related… compared with hydroxyurea and phlebotomy (very low certainty).
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
Long‐term red cell transfusion may leads to lower serious adverse events as a result of sickle cell‐related… compared with no transfusion (low certainty).
1 finding from 1 review
Serious adverse events (surgery‐related adverse effects within 30 days) · people with a low platelet count
1 finding from 1 review
Serious adverse events during the study period · children with acute postoperative pain
It is very uncertain whether diclofenac changes serious adverse events during study period № of participants: 60 (1… compared with paracetamol (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Adverse events ‐ increase in symptoms, injuries, or serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Serious adverse events, ‐ in total population randomised ‐ hypoglycaemia · critically ill patients
Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).
1 finding from 1 review
Serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus… compared with control (very low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with regular salbutamol (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found